

IMPROVED IMPACT ON CLINICAL OUTCOMES & REDUCED COSTS: Switching amino acid-based formulas



**Amino acid-based formulas (AAF)
with medium chain triglycerides
are important for managing:**



Cow's milk protein
allergy (CMPA)



Multiple
food allergies



Eosinophilic
GI disorders,
e.g. EoE



Food protein induced
enterocolitis
syndrome (FPIES)



Fat malabsorption &
malabsorptive conditions, e.g.
short bowel syndrome (SBS)

STUDY FOCUS



OBJECTIVE: Evaluate the clinical and economic impact of switching children <18 years from one AAF (EleCare®) to another (Alfamino®) during the 2022 U.S. formula shortage in post-acute care settings.

DESIGN: Retrospective analysis pre- (6 months prior) and post-switch (1,3,6 months after) of tolerance, gastrointestinal (GI) and allergy symptoms, healthcare resource utilization (HCRU), and associated costs.

TOTAL PARTICIPANTS

402
children

PARTICIPANT AGE

1–3 years
43% of
participants

STUDY TIMEFRAME

2022
formula
shortage

Formula
Studied

Alfamino
Infant Junior

Elecare™
Infant

Elecare™
Junior

% MCT**
of total fat

43%

65%


33%

33%


RESULTS



% OF GI INTOLERANCE SYMPTOMS



TOTAL ASSOCIATED COSTS



DISCUSSION AND CONCLUSION



Alfamino had a greater % of MCT as total fat, and it is possible that this may have attributed to improved GI symptoms as MCTs help with fat absorption.

Children in post-acute care settings who transitioned to an alternate amino acid-based formula (**Alfamino**) experienced significantly improved:

✓ **CLINICAL OUTCOMES**

58% less reports of
GI intolerance symptoms
after switching§

✓ **HEALTHCARE VISITS**

70% fewer mean
healthcare visits¶

✓ **ASSOCIATED COSTS**

86% reduction in
total associated costs#

**SCAN to see the author
present the study details**



** MCT = Medium Chain Triglycerides

† GI intolerance symptoms included abdominal distension, constipation, diarrhea, flatulence and nausea and vomiting

‡ Healthcare visits included outpatient, inpatient, emergency department, urgent care, telemedicine, and other

§ 148 patients pre-switch vs. 61 patients at 1 month post-switch

¶ A mean of 76 visits pre-switch vs. a mean of 23 visits at 1 month post-switch

\$670K total cost vs. \$93K cost at 1 month post-switch

The complete publication may be accessed online: Improved Impact on Clinical Outcomes and Reduced Cost of Care Associated With Switching Hypoallergenic Amino Acid-Based Formulas.

REFERENCE: Thakkar K., Cekola P., Boccella J., Desai A., Kumar P., Mondal S., Vijaykadam Y., Samal C., Klosterbuer A. *Sage Open Pediatrics* 2025;12: 1–11.